s 186

S186 is a kind of sodium salts of calcium-acetylpropylamine phosphonate(APA); and is a new agent of strontium-specific chelating.

Sodium hexacyclonate is a biochemical.

BMS 186318 is a human immunodeficiency virus (HIV) protease inhibitor designed to examine the possibility of developing resistance when two protease inhibitors are used together in recombination.

OTS186935 FA 是一种蛋白甲基转移酶 SUV39H2 抑制剂。OTS186935 FA在 MDA-MB-231 乳腺癌细胞和 A549 肺癌细胞中抑制肿瘤的生长。

Irbesartan (SR-47436) 是一种 1 型血管紧张素 II 受体拮抗剂，IC50为1.3 nM。

Irbesartan-d4 (Irbesartan D4) 是 Irbesartan 的氘代化合物，是血管紧张素受体阻滞剂，可用于研究心血血管疾病。

OTS186935 is a inhibitor of protein methyltransferase SUV39H2(IC50 of 6.49 nM).

OTS186935 trihydrochloride is a protein methyltransferase inhibitor of SUV39H2(IC50 of 6.49 nM).

Irbesartan is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. It selectively and competitively blocks the binding of angiotensin II to the angiotensin I receptor.

Omapatrilat is a metalloprotease ACE and NEP dual inhibitor (Ki: 0.64 and 0.45 nM, respectively).

S18616 Hydrochloride 是一种选择性且高效的 alpha2-肾上腺素受体激动剂。

OTS186935 hydrochloride 是蛋白甲基转移酶 SUV39H2 的有效抑制剂 (IC50: 6.49 nM)。OTS186935 hydrochloride 在小鼠异种移植模型中，能够明显抑制肿瘤生长，且没有明显毒性。OTS193320 hydrochloride 能够调节癌细胞中 γ-H2AX 的产生。

BMS-37 is a novel inhibitor of PD-1/PD-L1 immune checkpoint.

BMS-186511 is a Farnesyltransferase (FT) inhibitor with potential anticancer activity. BMS-186511 is a bisubstrate analogue inhibitor of FT, would inhibit the malignant growth properties of a cell line established from malignant schwannoma of an NF1 patient. Following treatment with BMS-186511 , ST88-14 cells became flat, nonrefractile, were contact-inhibited, and lost their ability to grow in soft agar. BMS-186511 was found to specifically inhibit FT, but not geranylgeranyltransferase I, a closely related enzyme. Thus, it is conceivable that FT inhibitors may ultimately become the first generation of drugs against the malignant phenotype in NF1 based on rational insights into the mechanism of action of neurofibromin.

Betamethasone 21-phosphate is a synthetic glucocorticoid.1It prevents increases in macrophage and eosinophil numbers in bronchoalveolar lavage fluid (BALF) and decreases in blood leukocyte numbers in a guinea pig model of parainfluenza-3 viral infection when administered at a dose of 8 mg/kg but does not prevent airway hyperresponsiveness after infection.2Betamethasone 21-phosphate inhibits cell infiltration into the aqueous humor in a rat model of endotoxin-induced uveitis when administered topically or subcutaneously at doses of 0.01-1% or 1 mg/kg, respectively.3It increases maximal lung pressure volume curves in fetal sheep when administered to pregnant ewes at 0.75 gestation at doses of 80 and 170 μg/kg.1Betamethasone 21-phosphate increases body weight, impairs learning and memory, increases anxiolytic behavior, and reduces hippocampal neurogenesis in CD-1 mice but reduces body weight and increases neurogenesis with no effect on anxiety in high-anxiety DBA/2 mice when administered at a dose of approximately 25 mg/kg per day in the drinking water for seven weeks.4Formulations containing betamethasone 12-phosphate and betamethasone acetate have been used in the treatment of severe allergic conditions and a variety of immune-related conditions. 1.Loehle, M., Schwab, M., Kadner, S., et al.Dose-response effects of betamethasone on maturation of the fetal sheep lungAm. J. Obstet. Gynecol.202(2)186.e181-186.e187(2010) 2.Leusink-Muis, A., Ten Broeke, R., Folkerts, G., et al.Betamethasone prevents virus-induced airway inflammation but not airway hyperresponsiveness in guinea pigsClin. Exp. Allergy29(Suppl. 2)82-85(1999) 3.Tsuji, F., Sawa, K., Kato, M., et al.The effects of betamethasone derivatives on endotoxin-induced uveitis in ratExp. Eye Res.64(1)31-36(1997) 4.Aiello, R., Crupi, R., Leo, A., et al.Long-term betamethasone 21-phosphate disodium treatment has distinct effects in CD1 and DBA/2 mice on animal behavior accompanied by opposite effects on neurogenesisBehav. Brain Res.278155-166(2015)